Drug Profile
Research programme: dual CCR2/CCR5 antagonists - Novartis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Novartis
- Class Indoles; Small molecules
- Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Austria (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland (PO)
- 04 Sep 2008 Preclinical trials in Autoimmune disorders in Austria (unspecified route)